PainChek Narrows Grant Support as Loss Widens and Auditor Flags Going Concern

PainChek Ltd ( (AU:PCK) ) has provided an update.

PainChek Limited reported half-year revenue from continuing operations of $1.73 million for the six months to 31 December 2025, up 5% year on year, but total revenue fell 42% to $1.76 million due to a sharp reduction in grant income. The company’s net loss attributable to members widened by 42% to $4.70 million, net tangible assets per share eased to 1.2 cents from 1.3 cents, no dividends were declared, and its auditor highlighted a going concern emphasis of matter, underscoring ongoing financial pressures and funding risks for shareholders.

The results indicate that while core operating revenue is growing modestly, PainChek remains reliant on external funding and faces profitability and balance sheet challenges. The going concern emphasis may affect investor sentiment and underscores the importance of future capital management and execution of its growth strategy to stabilise its financial position in a competitive health technology market.

The most recent analyst rating on (AU:PCK) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on PainChek Ltd stock, see the AU:PCK Stock Forecast page.

More about PainChek Ltd

PainChek Limited is a healthcare technology company that develops and commercialises digital tools for pain assessment. Its primary product suite focuses on clinical pain monitoring and evaluation, targeting healthcare providers and care facilities seeking objective, technology-driven methods to assess patient pain levels.

Average Trading Volume: 165,447

Technical Sentiment Signal: Sell

Current Market Cap: A$36.58M

Learn more about PCK stock on TipRanks’ Stock Analysis page.